Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2025.02.26
ag真人平台官方：关于依诺肝素钠注射液获得阿根廷药品注册批件的公告
2025.02.18
ag真人平台官方：关于获得药物临床试验批准通知书的公告
2025.02.14
ag真人平台官方：关于获得GMP证书的公告
2025.01.24
ag真人平台官方：2024年度业绩预告
2025.01.02
ag真人平台官方：关于签订分销协议的公告
2024.12.06
ag真人平台官方：关于延长员工持股计划存续期的公告
2024.12.06
ag真人平台官方：第六届董事会第十三次会议决议公告
2024.08.30
ag真人平台官方：2024年半年度报告摘要
2024.07.12
ag真人平台官方：2024年半年度业绩预告
2024.04.30
ag真人平台官方：关于续聘会计师事务所的公告
第一页
上一页
1
2
3
4
5
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
